Study Looks at Future Directions in CTEPH Patient Care

by Phyllis Hanlon, Contributing Writer In 1967, doctors performed the first pulmonary endarterectomy (PEA) (also known as pulmonary thromboendarterectomy or PTE) – surgery to remove old blood clots from the pulmonary arteries. This operation continues to be the first recommended treatment for patients with chronic thromboembolic pulmonary hypertension (CTEPH), since it can potentially reduce or

June 28th, 2017|

With Addition of Two Sites, U.S. Patients Have Access to Care from 52 PHA-Accredited Health Care Facilities

Silver Spring, Md. (June 21, 2017) - With the addition of two newly Pulmonary Hypertension Association (PHA)-accredited health care sites, more U.S. patients have access to care from facilities that have completed a rigorous review process for providing specialized pulmonary hypertension (PH) care. The University of New Mexico School of Medicine PH Program in

June 22nd, 2017|

M.D. Candidate Matthew L. Moreno Recognized for Work in PH Care for Minorities

The Pulmonary Hypertension Association (PHA) congratulates Matthew L. Moreno, an M.D. Candidate at the University of Kansas School of Medicine, for his recent recognition by the American Medical Association (AMA). Moreno's connection to pulmonary hypertension (PH) is through his support for PH Care for All, an initiative led by Vinicio de Jesus Perez, MD, FCCP, FAHA, and Arunabh Talwar, MD. Moreno's efforts

June 20th, 2017|

Modified Functional Classification System May Help Predict Pediatric PH Morbidity and Mortality

by Phyllis Hanlon, Contributing Writer Adults diagnosed with pulmonary hypertension (PH) are frequently assigned a functional classification during a clinic visit. The functional classification is a way to classify how limited patients are by their disease, and has been used by many physicians and scientists to track disease progress. The scale ranges from functional classification

June 14th, 2017|

PHA Completes First Comprehensive Community-wide Survey

As a member of the Pulmonary Hypertension Association (PHA) Board of Trustees and Chair of the new Strategic Planning Committee, I am proud to present the results from our first comprehensive community-wide survey. Until this survey, PHA had never formally gone to the pulmonary hypertension (PH) community to learn whether, and to what degree,

June 8th, 2017|

PHA Receives Award to Study Support Groups’ Impact on Patient Health

Silver Spring, Md. (June 8, 2017) - PHA is the proud recipient of an award from the Robert Wood Johnson Foundation (RWJF) President’s Staff Award. PHA will use this one-time award of $25,000 to collect data through its Pulmonary Hypertension Care Center (PHCC) program’s Pulmonary Hypertension Association Registry (PHAR) to analyze the impact and

June 7th, 2017|

Drug-Induced PH: Causes, Treatment and Predictions

by Phyllis Hanlon, Contributing Writer In 1965, an unusually large number of cases of pulmonary arterial hypertension (PAH), which was previously considered exceedingly rare, was reported in Switzerland, Germany and Austria. At the time, researchers found a link between this condition and exposure to a weight loss and mood disorder drug called Aminorex. Since drug-

May 31st, 2017|

Experts Debate Need for More PH Therapies

A symposium sponsored by the National Institutes of Health (NIH) Clinical Center Critical Care Medicine Department (CCMD) and the Pulmonary Hypertension Association (PHA) created a unique opportunity for medical experts to discuss how to recognize and manage PH patients with complex presentations of the disease, and publicly debate a controversial topic: will PH patients with

May 25th, 2017|